Document is current
Any future updates will be listed below
-
Authors
Muniyandi, Anbukkarasi
Hartman, Gabriella D.
Sishtla, Kamakshi
Rai, Ratan
Gomes, Cátia
Day, Kristina
Song, Yang
Masters, Andi R.
Quinney, Sara K.
Qi, Xiaoping
Woods, Hailey
Boulton, Michael E.
Meyer, Jason S.
Vilseck, Jonah Z.
Georgiadis, Millie M.
Kelley, Mark R.
Corson, Timothy W.
-
Funding
Funding for this research was provided by:
National Eye Institute (F31EY035171, R01EY031939, R01EY031939, R01EY031939)
National Cancer Institute (P30CA082709, P30CA082709)
National Heart, Lung, and Blood Institute (R01HL140961)
Riley Children's Foundation
Tom Wood Lexus Foundation
Research to Prevent Blindness
Canada Foundation for Innovation
- License Information
-
More Information
Article History
Received: 9 July 2024
Accepted: 16 December 2024
First Online: 5 January 2025
Declarations
:
: MRK and TWC are named inventors on patents related to this work, licensed to Apexian Pharmaceuticals and Opus Genetics. MRK is a consultant to Opus Genetics and CSO and cofounder of Apexian Pharmaceuticals, which developed APX3330 for oncology, as well as APX2009 investigated in this manuscript. The other authors declare no conflicts of interest. Neither Apexian Pharmaceuticals nor Opus Genetics had any input or control over the contents of this manuscript.
